RedHill Triumphs in New York Supreme Court, Awarding $10 Million Against Kukbo

RedHill Biopharma's Legal Victory in New York Supreme Court

In a significant ruling, the New York Supreme Court has upheld its prior summary judgment in favor of RedHill Biopharma Ltd. (Nasdaq: RDHL). The decision reinforces the integrity of contractual obligations in the biopharmaceutical industry. The court dismissed the defense presented by Kukbo Co. Ltd., maintaining that they were in breach of both the initial subscription and subsequent exclusive license agreements with RedHill. This ruling marks a pivotal moment for RedHill, solidifying their rights and obligations under the agreements with Kukbo.

On September 29, 2025, RedHill announced that the New York Supreme Court had granted a total of approximately $10 million in awards stemming from related court actions. This comprised an $8.25 million initial award alongside a subsequent $1.82 million allocation for legal costs and statutory interest. The court clearly stated its position that RedHill had complied with its contractual obligations, countering Kukbo's claims that sought to absolve them from responsibility.

RedHill’s CEO expressed satisfaction with the ruling, interpreting it as a reinforcement of the company's commitment to uphold its contractual agreements in a challenging legal landscape. Kukbo maintains the option to appeal the court's decision; however, the ruling stands as a significant benchmark for the enforcement of contractual agreements, especially in the biopharma sector.

This legal win comes alongside another recent success for RedHill. The company also secured an attachment grant against Kukbo from Korea’s Incheon District Court, allowing RedHill to order a court seizure of Kukbo’s assets. This legal maneuver aims to protect RedHill’s financial interests while the case unfolds.

About RedHill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focusing on the development and commercialization of drugs aimed at treating gastrointestinal diseases, infectious diseases, and various cancers. One of their key products, Talicia®, is FDA approved for treating H. pylori infections in adults. Besides Talicia, RedHill is progressing multiple late-stage clinical development programs targeting other health-related issues, including COVID-19, Crohn's disease, and various cancers.

RedHill is not only committed to developing innovative therapeutic solutions but also to maintaining strict compliance with industry regulations and standards. Their ongoing projects aim to address critical unmet medical needs, emphasizing their role as a leader in biopharmaceutical development. As the company prepares for future opportunities, they continue to advocate for a strong legal and regulatory framework that supports their innovative pursuits while ensuring fair competition in the market.

The recent favorable ruling is likely to bolster confidence among investors and partners, positioning RedHill for further advancements and potential collaborations in the biopharmaceutical landscape. As such, RedHill remains a company to watch in the evolving field of healthcare and medicine, poised to make significant contributions to public health and wellness.

For more information about RedHill Biopharma and their ongoing projects, visit their official website at RedHill Biopharma.